Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7742963 | 0.81 | — | — | |
| SCHEMBL7360733 | 0.77 | GABRR1 (0.31) | — | |
| SCHEMBL5150388 | 0.76 | CPB2 (0.39) | CPB2GSRRNPEP | |
| SCHEMBL3952652 | 0.73 | GSR (0.38) | CPB2GSRRNPEPGNAI3GNAO1 | |
| SCHEMBL7748340 | 0.72 | GAA (0.30) | — | |
| SCHEMBL15529854 | 0.71 | CHRM2 (0.34) | CPB2GSRRNPEP | |
| SCHEMBL6228775 | 0.71 | FFAR4 (0.41) | CPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL22558026 | 0.70 | FFAR4 (0.41) | CPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL5133687 | 0.69 | GSR (0.35) | CPB2GSRRNPEP | |
| SCHEMBL5133688 | 0.69 | GSR (0.35) | CPB2GSRRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CPB2 284/4885GSR 4555/4885RNPEP 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.